The effect of hepatobel on fatty liver

The effect of hepatobel on fatty liver parameters in patients with fatty liver disorder

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141027019705N2

Enrollment

Registered

2019-06-16

Start date

2019-07-10

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with fatty liver.

Interventions

Intervention 1: Intervention group: The number of participants in this group is 30. The group has a fatty liver that receives hepatobel capsules for 6 weeks. Intervention 2: Control group: The number

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Not having known heart disease Not having known kidney disease Having abnormal liver parameters

Exclusion criteria

Exclusion criteria: Unwilling to continue study Find sensitivity to hepatobel capsules

Design outcomes

Primary

Measure	Time frame
Improve liver function. Timepoint: Measurement of fatty liver enzymes in the beginning of the study (before the start of the study) and 6 weeks after the intervention. Method of measurement: Measuring liver enzymes using biochemical kits.;Normalizing Fatty Liver Indices (such as FLI and HSI Indicators). Timepoint: Measurement of fatty liver indices in the beginning of the study (before the start of the study) and 6 weeks after the intervention. Method of measurement: Measuring liver enzymes using biochemical kits.	—

Measure

Time frame

Improve liver function. Timepoint: Measurement of fatty liver enzymes in the beginning of the study (before the start of the study) and 6 weeks after the intervention. Method of measurement: Measuring liver enzymes using biochemical kits.;Normalizing Fatty Liver Indices (such as FLI and HSI Indicators). Timepoint: Measurement of fatty liver indices in the beginning of the study (before the start of the study) and 6 weeks after the intervention. Method of measurement: Measuring liver enzymes using biochemical kits.

—

Secondary

Measure	Time frame
Improve blood sugar. Timepoint: Measurement of blood sugar in the beginning of the study (before the start of the study) and 6 weeks after the intervention. Method of measurement: Measuring blood sugar using biochemical kits.;Improve blood bilirubin. Timepoint: Measurement of blood bilirubin in the beginning of the study (before the start of the study) and 6 weeks after the intervention. Method of measurement: Measuring blood bilirubin using biochemical kits.	—

Measure

Time frame

Improve blood sugar. Timepoint: Measurement of blood sugar in the beginning of the study (before the start of the study) and 6 weeks after the intervention. Method of measurement: Measuring blood sugar using biochemical kits.;Improve blood bilirubin. Timepoint: Measurement of blood bilirubin in the beginning of the study (before the start of the study) and 6 weeks after the intervention. Method of measurement: Measuring blood bilirubin using biochemical kits.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Salehi

Arak University of Medical Sciences

m_salehi@razi.tums.ac.ir+98 86 3417 3645

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026